» Articles » PMID: 38213731

Construction and Validation of a Gastric Cancer Diagnostic Model Based on Blood Groups and Tumor Markers

Overview
Journal J Cancer
Specialty Oncology
Date 2024 Jan 12
PMID 38213731
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study is to explore the value of combined detection of ABO blood group and tumor markers in the diagnosis of gastric cancer. A total of 3650 gastric cancer patients treated in our center from January 2015 to December 2019, and 5822 controls were recruited, and divided into training set and validation set according to 7:3. The diagnostic and predictive model of gastric cancer was constructed by binary logistic regression method in the training set. The diagnostic value of the prediction model for gastric cancer was evaluated by calculating the prediction probability P value and drawing the Receiver operating characteristic (ROC) curve, and was verified in the validation set. The Area under the curve (AUC) of the diagnosis and prediction model in the training set was 0.936 (95%CI: 0.926-0.941), the sensitivity was 81.66%, and the specificity was 98.61%. In the validation set, the AUC was 0.941 (95%CI: 0.932-0.950), the sensitivity was 82.33%, and the specificity was 99.02%. Furthermore, the diagnostic model obtained in this study had a high diagnostic value for early gastric cancer patients in the healthy population (AUC of training set, validation set and total population were 0.906, 0.920 and 0.908, respectively). We constructed a diagnostic model for gastric cancer including blood group and tumor markers, which has high reference value for the diagnosis of gastric cancer patients, and the model can better distinguish early gastric cancer from healthy people.

Citing Articles

Diagnostic Accuracy of Artificial Intelligence in Endoscopy: Umbrella Review.

Zha B, Cai A, Wang G JMIR Med Inform. 2024; 12:e56361.

PMID: 39093715 PMC: 11296324. DOI: 10.2196/56361.


Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements.

Sheikh R, Naqvi S, Al-Sulami A, Bayamin M, Samsahan A, Baig M CNS Neurol Disord Drug Targets. 2024; 24(1):74-82.

PMID: 38956913 DOI: 10.2174/0118715273306577240612053957.


Predictive efficacy of combined tumor markers and gastrin for recurrence after endoscopic submucosal dissection in early gastric cancer patients.

Zhao B, Liu C, Ni S, Zhang Q Am J Transl Res. 2024; 16(5):2059-2069.

PMID: 38883344 PMC: 11170613. DOI: 10.62347/VOTO5604.

References
1.
Sun X, Ai L, Feng Y . The Value of ABO Blood Group and Complete Blood Count for the Prognosis Analysis of Gastric Cancer Patients. Onco Targets Ther. 2020; 13:4627-4633. PMC: 7260541. DOI: 10.2147/OTT.S248065. View

2.
Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J . Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2001; 16(3-4):105-10. PMC: 3851416. DOI: 10.1155/2000/595492. View

3.
Song H, Shin M, Kim H, Piao J, Choi J, Hwang J . Sex-specific differences in the association between ABO genotype and gastric cancer risk in a Korean population. Gastric Cancer. 2012; 16(2):254-60. DOI: 10.1007/s10120-012-0176-z. View

4.
Franchini M, Liumbruno G, Lippi G . The prognostic value of ABO blood group in cancer patients. Blood Transfus. 2015; 14(5):434-40. PMC: 5016303. DOI: 10.2450/2015.0164-15. View

5.
Beasley W . Blood groups of gastric ulcer and carcinoma. Br Med J. 1960; 1(5180):1167-72. PMC: 1967187. DOI: 10.1136/bmj.1.5180.1167. View